Le Lézard
Classified in: Health, Business
Subjects: STOCK/OTHER MARKET NEWS, Restructuring / Recapitalization

PureK Holdings Corp. Announces Completion of Qualifying Transaction


PHOENIX, Dec. 08, 2020 (GLOBE NEWSWIRE) -- PureK Holdings Corp?. (the "Company") (TSX Venture: PKAN), formerly AF1 Capital Corp., is pleased to announce that it has completed its previously announced qualifying transaction (the "Qualifying Transaction") pursuant to the policies of the TSX Venture Exchange ("TSXV"). For additional information about the Qualifying Transaction, please see the Company's news release dated November 23, 2020 and the filing statement of the Company dated November 20, 2020 (the "Filing Statement"), which are available at www.sedar.com.

Trading in the common shares of the Company (the "Common Shares") is expected to commence on the TSXV under the symbol "PKAN" on or about December 10, 2020 following the issuance by the TSXV of its final bulletin in respect of the Qualifying Transaction.

The Qualifying Transaction was completed in accordance with the terms of the previously announced business combination agreement dated November 20, 2020 ?(the "Business Combination Agreement") ?among the Company, Heavenly Rx Ltd. ("Heavenly"), Heavenly Rx, LLC ("Heavenly Subco"), PureKana, LLC ("PureKana"), ?Cody J. Alt and Jeff Yauck (the "PureKana Founders").?

Pursuant to the terms of the Business Combination Agreement:

AF1 Subco is a wholly-owned subsidiary of the Company.? In connection with the Merger, the Company indirectly assumed Heavenly Subco's ?obligations under outstanding promissory notes held by the PureKana Founders in the aggregate ?principal amount of US$?6,934,298?.?

Immediately following the Merger, Heavenly distributed to its shareholders an aggregate of ??1,349,934 ??Common Shares, and contributed to certain arm's length third party limited partnerships an ?aggregate of 2,050,000 Common Shares, and the ?PureKana Founders sold the 1,025,000 Series 1 Preferred Shares ?to arm's length parties ?for aggregate gross proceeds of US$8,200,000.?

As a result of the Merger and following the completion of the Consolidation, the Company has approximately ???????7,005,626 Common Shares and ?1,025,000 ?Series 1 Preferred ?Shares outstanding and has reserved for issuance 12,500 Common Shares pursuant to stock options and 7,500 Common Shares pursuant to agent's options.

The board of directors of the Company now consists of four directors: Paul Norman, Jeff Yauck, Cody Alt and Michael Galloro. The officers of the Company are Kathy Casey (Chief Executive Officer) and Brian Meadows (Chief Financial Officer and Corporate Secretary). The directors and officers of the Company, as a group, beneficially own, or control or direct, directly or indirectly, 2,890,907 Common Shares, which are subject to escrow restrictions as further described in the Filing Statement.

Early Warning Disclosure Pursuant to National Instrument 62?103

In connection with the Qualifying Transaction, each of Jeff Yauck and Cody Alt ?acquired ownership, control or direction over Common Shares requiring disclosure pursuant to ?the early warning requirements of applicable securities laws.?

Prior to the completion of the Qualifying Transaction, each of Jeff Yauck and Cody Alt had no ownership of, or ??exercised control or direction over, any voting or equity securities of the Company. In connection with the ??Qualifying Transaction, each of Jeff Yauck and Cody Alt acquired ownership of 1,409,063 Common Shares ???representing approximately 20.1% of the issued and outstanding Common Shares on a non-diluted ??basis and 12.9% on a fully diluted basis in accordance with the terms of the Merger.?

Each of Jeff Yauck and Cody Alt: (i) acquired the Common Shares in ?connection with the Qualifying Transaction; (ii) holds the Common Shares for investment purposes; ?and (iii) does not have any current intentions to increase or decrease his beneficial ownership or ?control or direction over any additional securities of the Company. Each of Jeff Yauck and Cody Alt may, from time to time and depending on market and other conditions, ?acquire additional Common Shares through market transactions, private agreements, treasury ?issuances, convertible securities or otherwise, or may sell all or some portion of the Common Shares ?they each own or control, or may continue to hold the Common Shares.?

Copies of the early warning reports may be obtained from Brian Meadows, Chief Financial Officer, PureK Holdings Corp., +1 (855) 553-7441, [email protected].

About PureK Holdings Corp.

PureK Holdings Corp. indirectly owns a 50.1% ?equity interest in PureKana, LLC. PureKana is recognized as a Top 10 cannabidiol ("CBD") brand in the United States and has operated a ?profitable direct-to-consumer online business since its inception in 2017. Its product lineup includes high ?quality CBD that can be consumed in the form of tinctures, capsules, topicals, patches, and gummies. PureKana's brand and direct-to-consumer marketing expertise has helped to establish ?PureKana as one of the leading online CBD brands in the United States. The online presence is now being expanded into broader retail outlets. PureKana operates legally in the ?jurisdictions where it carries on business.?

For further information:

Brian Meadows
Chief Financial Officer
?Ph: +1 (855) 553-7441
Email: [email protected]

Forward-Looking Information

Certain statements contained in this news release, such as the anticipated trading day on the TSXV, constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable the CBD industry and to the Company as set forth in the Company's Filing Statement in respect of the Qualifying Transaction filed under the Company's profile at www.sedar.com. The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.   

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ?policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press ?release.?



These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: